ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint

• ArriVent reported its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed the main goal.
• Independent review showed no meaningful improvement versus chemotherapy, raising uncertainty over the program’s near-term regulatory path.
• Secondary measures indicated clinical activity, with an early signal suggesting overall survival may favor firmonertinib as data mature.
• Safety matched prior studies, with no new safety issues flagged.
• Results were announced now; no future presentation timing was disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9840447) on October 06, 2026, and is solely responsible for the information contained therein.